Dynamics of structural and functional changes of the heart and the levels of GDF 15 and NTproBNP on the candesartan and ramipril therapy in patients with heart failure with preserved ejection fraction after myocardial infarction on the background of arter

Authors

  • Ya. V. Zemlyaniy

DOI:

https://doi.org/10.14739/2310-1210.2014.2.25232

Keywords:

heart failure with preserved ejection fraction, candesartan, ramipril, myocardial infarction, hypertension

Abstract

Abstract. Chronic heart failure (CHF) is actual medical problem around the world and in Ukraine. Almost 50% of these patients have heart failure with preserved ejection fraction. CHF is the result of many complications and cardiovascular disease, such as coronary heart disease, including myocardial infarction and hypertension. Despite the prevalence of heart failure with preserved ejection fraction a common strategy for the treatment of this disease has not yet been developed. This is due to the limited number of controlled studies in these patients. One of the most effective drugs in the treatment of heart failure with preserved ejection fraction after myocardial infarction are candesartan and ramipril. Determining the dynamics of GDF 15 and NTproBNP along with those of echocardiography is promising for evaluating the effectiveness of treatment of patients with heart failure with preserved ejection fraction after myocardial infarction in the background of arterial hypertension.

The aim of research. To determine the dynamics of structural and functional changes of the heart and the levels of GDF 15 and NTproBNP on the ramipril and candesartan therapy in patients with heart failure and preserved ejection fraction after myocardial infarction on the background of arterial hypertension.

Materials and methods. 38 patients with heart failure with preserved left ventricular ejection fraction (EF>45%) after myocardial infarction with comorbidity arterial hypertension were included into the study. Dynamics of structural and functional changes of the heart and the levels of GDF 15 and NTproBNP on the ramipril and candesartan therapy for 12 weeks (mean age 64,3 ± 1,3 years) were investigated. Prescription myocardial infarction ranged from 2 months to 3 years. Patients were divided into 2 groups. The first group in addition to the basic treatment received candesartan (KASARK "Arterium", Ukraine) at a mean dose 18,5 ± 2,1 mg daily. Patients of the second group received ramipril (RAMIMED, «Medochemie Ltd.», Iceland/Cyprus) at a mean dose 5,8±0,6 mg daily.

Results. In patients receiving candesartan was observed decreased hypertrophy with significant thinning left ventricular walls, decreased  left ventricular mass index (5,4%, p<0,05), MVA (11,0%, p<0,05), increase E' (12,5%, p<0,05), reduction ratio E/E' (10,9%, p<0,05) and decreased left atrium volume index (12,0%, p<0,05).  Patients with ramipril therapy have significant thinning posterior left ventricular wall (6,7%, p<0,05), decreased  left ventricular mass index (5,9%, p<0,05) and left atrium volume index (10,1%, p<0,05). On the candesartan therapy for 12 weeks was observed a significant reduction the levels of GDF 15 (Δ (%)=-27±4,65) and NTproBNP (Δ(%)=-22±12,7) in serum. Patients with ramipril therapy also contributed to a significant decrease levels of GDF 15 (Δ (%)=-25±3,48) and NTproBNP (Δ(%)=-16±12,6). On the background of candesartan therapy was a significant increased the distance of the 6-minute walking test (26,1%; p<0,05). Ramipril therapy also led to a significant increased the distance of the 6-minute walking test (13,1%; p<0,05).

Conclusion. Intaking of the candesartan and ramipril contributed to decreasing LV. On the background of candesartan therapy was observed more substantial improvement of LV diastolic function with decreasing E/E' compared with ramipril. Candesartan and ramipril therapy led to a lowering of GDF 15 and NTproBNP, while the dynamics of NTproBNP in patients receiving candesartan was more significant. Candesartan and ramipril therapy provided to improve the clinical condition of patients.

 

References

Voronkov L.H. A patient with heart failure in Ukraine: an analysis across the patient population studied in the framework of the National sectional study UNIVERS. Sertseva nedostatnist 2012; 1: 8-13.

Voronkov L.H., Amosova K.M., Bagrii A.E. Rekomendatsii z diagnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2012) [Guidelines for the diagnosis and treatment of chronic heart failure (2012)]. Kyiv, 2012. 106 p.

Lupanov V.P. Angiotensin converting enzyme inhibitors in the treatment and prognosis of patients with CHD and chronic heart failure. Focus on ramipril. Arterialnaia hipertenziia 2010; 1(9): 12-15.

Muhmatulina D.M., Shalaev S.V. Comparative efficacy of candesartan and enalapril in patients with chronic heart failure due to hypertension and paroxysmal atrial fibrillation. Vrach-aspirant 2007; 6 (21): 465-478.

Sekerko S.A. Clinico-hemodynamic assessment of the effectiveness of telmisartan and enalapril in the correction of left ventricular diastolic dysfunction in patients with ischemic heart disease. Aspirantskii vestnik Povolzhia 2009; 78: 60-66.

Sidorenko B.A., Preobrazhenskii D.V., Soplevenko A.V. Candesartan - new blocker AT1 angiotensin receptor: pharmacology and experience especially use in hypertension. Kardiologiia 2004; 44(1): 55-63.

Tereshchenko S.N., Zhyrov I.V. Place of angiotensin II receptor antagonists in the treatment of chronic heart failure. Results of the program CHARM. Zhurnal Serdechnaia Nedostatochnost 2006; 7(3): 146-149.

De Denus S., Lavoie J., Ducharme A., O’Meara E., Racine N., Sirois M.G., Neagoe P.A., Zhu L., Rouleau J., White M. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J. Cardiol 2012; 28(1): 62-68.

Jiamsripong P., Honda T., Reuss C.S., Hurst R.T., Chaliki H.P., Grill D.E. Three methods for evaluation of left atrial volume. Eur. J. of Echocardiography 2008; 9: 351-355.

Kempf T., von Haehling S., Peter T., Allhoff T., Cicoira M., Doehner W., Ponikowski P., Filippatos G.S., Rozentryt P., Drexler H., Anker S.D., Wollert K.C. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1054-1060.

McMurray J.J., Adamopoulos S., Anker S.D. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur. Heart J 2012; 33: 1787-1847.

Nagueh S.F., Appleton C.P., Gillebert T.C. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. Journal of the American Society of Echocardiography. 2009; 22: 107-133.

Stahrenberg R., Edelmann F., Mende M. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur. J. Heart Fail. 2010; 12: 1309-1316.

Yip G.W.K, Wang M., Wang T. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008; 94: 573-580.

How to Cite

1.
Zemlyaniy YV. Dynamics of structural and functional changes of the heart and the levels of GDF 15 and NTproBNP on the candesartan and ramipril therapy in patients with heart failure with preserved ejection fraction after myocardial infarction on the background of arter. Zaporozhye Medical Journal [Internet]. 2014Jun.19 [cited 2024Dec.24];16(2). Available from: http://zmj.zsmu.edu.ua/article/view/25232

Issue

Section

Original research